Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Angiogenesis-VEGF
3. Angiogenesis-VEGF-C/D
4. VEGF and VEGFR tyrosine kinase
5. Strategies to inhibit VEGFR signaling
6. MuMAb VEGF A4.6.1
7. RhuMAb VEGF-Avastin
8. Blocking Ab differ from other agents
9. Anti-VEGF Ab prevents VEGF/VEGFR interaction
10. Potential effects of inhibiting VEGF
11. Anti-angiogenesis 'normalises' tumour vasculature
12. Anti-VEGF Ab modifies tumor vasculature
13. VEGF inhibition can induce capillary regression
14. Ranibizumab
15. Pegaptanib
16. 'Metronomic' anti-angiogenic chemotherapy
17. Preclinical models
18. Potential effects of anti-VEGF therapy
19. Anti-VEGFR2 mAb
20. Treatment of human xenograft tumors with DC101
21. VEGFR-2 blockade
22. VEGFR-2 block leads to increase in tumor hypoxia
23. Anti-VEGFR-2 mAb and gemcitabine
24. VEGFR-2 Ab IMC-1121b
25. Structure and properties of VEGF trap
26. Angiogenesis inhibitors in clinical trials
27. Conclusions (1)
28. Conclusions (2)
29. Inhibitors of lymphangiogenesis
30. Tumor lymphangiogenesis and metastasis
31. VEGF-C/D trap prevents VEGFR-3 signaling
32. VEGF-C/D trap prevents lymph vessels growth
33. Inhibition of lymphangiogenesis with VEGFR-3-Fc
34. Blocking metastasis to lymph nodes
35. Model of lymphatic metastasis
36. Model of prevention of lymphatic metastasis
37. Proteolytic processing of VEGF-C/D
38. VEGF in hematogenous and lymphatic spread
39. Antagonist monoclonal Abs to VEGFR-3
40. Soluble receptors (traps) and antagonist antibodies
41. Antagonist monoclonal antibodies to VEGFR-3
42. Mode of action of antagonist mAbs to RTKs
43. Functional properties of alpha-VEGFR-3 mAbs
44. Dermal lymphatic regeneration model in mouse
45. Systemic alpha-VEGFR-3 treatment
46. Angio- and lymphangiogenesis blocking
47. Alpha-VEGFR-3 inhibits growth of carcinomas
48. Alpha-VEGFR-3 inhibits metastasis of carcinoma
49. VEGF-C induces hypertrophy of lymphatic vessels
50. Alpha-VEGFR-3 inhibits lymph vessels hypertrophy
51. Alpha-VEGFR-3 reduces metastasis to lymph
52. The role of VEGFR-3 in inflammation
53. Expansion of the lymphatic network
54. Prevention of lymphatic hyperplasia
55. Alpha-VEGFR-3 modulates adaptive immunity
56. VEGF-C, VEGFR-3 and inflammation (1)
57. VEGF-C, VEGFR-3 and inflammation (2)
58. Rejection of renal transplants
59. Conclusions (3)

Topics Covered

• Antagonist monoclonal antibodies to VEGFR-3
• Mode of action of antagonist monoclonal antibodies
• Functional properties of antagonist antibodies to VEGFR-3
• In vivo effects of anti-VEGFR-3 treatment on physiological lymphangiogenesis
• Inhibition of pathological vessel growth in the cornea
• Anti-angiogenic effect of antibodies to VEGFR-3 in tumors
• Inhibition of lymphatic metastasis with antagonist antibodies to VEGFR-3
• Role of VEGFR-3 in normal and pathological immune response

Links

Series:

• Monoclonal Antibodies as Therapeutic Agents

Categories:

• Cancer

Therapeutic Areas:

• Cardiovascular & Metabolic
• Oncology

Talk Citation

Alitalo, K. and Pytowski, B. (2007, October 1). VEGF inhibitors for anti-angiogenic therapy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/SSHQ8214.
Export Citation (RIS)

Publication History

• Published on October 1, 2007
• Archived on May 31, 2018

Financial Disclosures

• Prof. Kari Alitalo has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
• Dr. Bronislaw Pytowski has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.